Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CMLSusan Branford, Timothy P. Hughes, David M. Ross et al.|Blood|2013Cited by 177
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinibWendy T Parker, Susan Branford, David T Yeung et al.|Blood|2016Cited by 65